logo

Hutchison China Meditech Ltd (HCM)



Trade HCM now with
  Date
  Headline
1/12/2022 6:08:30 AM HUTCHMED Gets Breakthrough Therapy Designation In China For HMPL-523 For Immune Thrombocytopenia
11/1/2021 1:10:30 AM HUTCHMED, AstraZeneca Begins SAMETA Phase III Trial Of Savolitinib With PD-L1 Inhibitor IMFINZI
9/8/2021 6:58:34 AM HUTCHMED, AstraZeneca Initiate SANOVO Phase III Trial Of ORPATHYS And TAGRISSO Combination For Lung Cancer In China
8/8/2021 8:58:46 PM Epizyme And HUTCHMED Collaborats To Develop & Commercialize TAZVERIK In Greater China
7/13/2021 2:31:18 AM HUTCHMED Announces First Commercial Sale Of ORPATHYS In China
7/1/2021 6:09:50 AM FDA Accepts Filing Of HUTCHMED’s Surufatinib NDA For Pancreatic And Extra-pancreatic Neuroendocrine Tumors
6/23/2021 2:05:42 AM AstraZeneca Says Orpathys Approved In China For Lung Cancer And MET Gene Alterations
6/6/2021 8:43:19 PM Innovent Releases Phase 1b Preliminary Results Of TYVYT + Fruquintinib As Treatment For Advanced Colorectal Cancer
3/29/2021 2:32:43 AM Hutchison China MediTech Begins Two International Phase I Studies Of HMPL-306
3/24/2021 9:36:16 AM HUTCHMED Agrees To Divest Non-Core OTC Joint Venture For $169 Mln
3/24/2021 3:36:09 AM HUTCHMED Begins Phase Ib/II Trial Of Surufatinib With Tislelizumab In Advanced Solid Tumors In U.S. And Europe
4/11/2016 11:45:28 AM Canaccord Starts Hutchison China Meditech Ltd (HCM.L) At Buy With $20 Price Target